Hemex
VC Fund
Liestal, Switzerland
Hemex is a VC fund in Liestal focused on Health Care and Biotechnology. As a swiss investment and consulting company headquartered close to the Basel global life sciences hub, our main focus is to bring innovative drugs, medical devices and in vitro diagnostics to the market.We specialize in supporting start-ups. Working closely with your management team, we offer tailored solutions to accelerate your project into asuccessful and sustainable business.Our team of life science, legal and financial professionals covers a wide range of expertise. From development support like preclinical/clinical trial management, regulatory affairs, quality assurance, CMC and medical affairs, to business coaching, marketing strategy, intellectual property creating and finding financing solutions, we know how to successfully bring a product from the lab to the market.Our offices in Switzerland, Germany and USA work closely with local health authorities, patient groups, contract research organizations and key opinion leaders.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 43%
Last updated:
For AI agents: llms.txt
Industries Hemex invests in
Stages Hemex invests in
Countries Hemex invests in
Investment Focus
Industry
- Health Care 5 (36%)
- Biotechnology 5 (36%)
- Medical 4 (29%)
- Medical Device 4 (29%)
- Life Science 3 (21%)
Stage
- Seed 4 (29%)
- Series A 3 (21%)
- Pre-Seed 1 (7%)
- Series B 1 (7%)
- Funding Round 1 (7%)
Country
- Switzerland 8 (57%)
- Sweden 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Annaida Technologies
|
Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. | Seed / Apr 29, 2025 | |
Hemotune
|
Hemotune is a medical device company that develops a therapeutic blood purification platform for treatment of health ailments. | $15.6M / Series B / Mar 25, 2024 | |
Bottneuro
|
Bottneuro offers a unique, non-invasive therapy for early- and moderate-stage Alzheimer's Disease patients using electrical stimulations of neurons and glia cells in the brain. Bottoneuro develops stimulation protocols using the NENI technology platform. | $4.3M / Convertible Note / Dec 15, 2022 | |
Aspivix
|
ASPIVIX is developing a new generation of medical devices that make gynecological procedures gentler and safer for women and gynecologists. The first device, CAREVIX, is designed to prevent cervix bleeding using a suction technology to replace traumatic tenaculum (forceps). | $5M / Series A / Nov 17, 2022 | |
|
Hemotune
|
Hemotune is a medical device company that develops a therapeutic blood purification platform for treatment of health ailments. | $7.5M / Series B / Apr 26, 2022 | |
Scailyte
|
Scailyte has established a data-driven biomarker discovery platform that leverages unique expertise in single-cell data analysis and artificial intelligence. We are utilizing this platform to discover a new class of biomarkers, which are defined by the molecular profiles of disease-associated cells. This phenotypic approach to biomarker discoveryis radically new and directly related to the biology of a disease, which maximizes the success rate for discovering sensitive and robust biomarkers. | $3.3M / Seed / Jun 09, 2020 | |
|
Annaida Technologies
|
Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. | $1M / Seed / Apr 09, 2020 | |
Resistell AG
|
Resistell is a antibiotic resistance test. | $4.1M / Series A / Dec 17, 2019 | |
|
Annaida Technologies
|
Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. | $163K / Pre-Seed / Jun 07, 2019 | |
Sleepiz
|
Sleepiz is a Zürich based startup with the aim to enable the medical community to take healthcare into the home environment. Sleepiz provides an easy and comfortable to use solution with a device that is simply placed on the bedside table. The device operates in a non-contact fashion and measures movements originating from heart contractions andbreathing patterns as well as body motions with medical grade accuracy.By making use of wireless millimeter wave technology, sensor fusion and artificial intelligence Sleepiz will in the future not only able to diagnose sleep disorders, but also to perform long-term monitoring. Thereby, the progression of chronic diseases can be monitored to allow faster intervention and better treatment. | $1.2M / Seed / May 29, 2019 | |
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Hemex invest in?
Hemex invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 14 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Hemex last invest?
The most recent investment recorded for Hemex closed in Apr 2025. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
